| A product of a mutant strain from Streptomyces tenebrarius was isolated and identified as a new component of Nebramycin-one of aniinoglycoside antibiotics: the tentative name is 98-23.Meanwhile, the biopotency of 9 8-23 was determined; the biological characteristics of the mutant strain were studied in detail. Referring to the industrial extraction process of aminoglycoside antibiotics, 98-23 was isolated and purified by macro porous ion-exchange resin and CM-Sephadex-C-25. By means of spectroscopic analyses(IR,MS,1H-NMR, 13C-NMR, 1H- 1H COSY, HOHAHA, HMQC), 98-23 has been identified as a new antibiotic member of the aminoglycoside group, and its chemical name is O-3-amino-6-O- (aminocarbonyl-3 -deoxy- α -D-glucopyranosyl-( 1 → 6)-O-[2-amino- 2,3 -dideoxy- α -D-glucopyranosyl-( 1 → 4)] -2-deoxy-D-streptamine. Through determination of MIC against commonly encountered and some important clinic bacteria and acute toxicity in mice, we found that 98-23 possesses a certainly biological activity; Moreover because the LD50 of 98-23 is only 500mg/kg, it has some clinic value. After investigation of the mutant's biological characteristics, we noticed that it's fermentation titer is relatively higher, and there is only a single active component in its' products .In addition, the mutant strain is genetically stable. Those characteristics give it a potentiality of industrialization .Qn this basis, we investigated a series of factors influencing the mutant's culture and fermentation .At last, the most appropriate condition was determined. Some extraction processes, such as sort of resin, pH condition of 7 ABSTRACT adsorption, rate of elution and method of crystallization, were researched; the yield and purity of product were improved. Considering the position of aminoglycoside antibiotics, 98-23 is worthy of research further. This paper mainly accomplished some parts of preliminary research works.
|
PDF Full Text Request